Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | THPO | P40225 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433661 | 0.78 | BRD4 (0.42) | HIF1ANFKB1TSHRALOX15TDP1 | |
| SCHEMBL8943828 | 0.78 | ALDH1A1 (0.41) | TSHRTDP1LMNAALDH1A1MEN1 | |
| SCHEMBL10949896 | 0.78 | MAPT (0.38) | HIF1ATSHRALOX15KDM4ETDP1 | |
| SCHEMBL10953516 | 0.78 | HDAC3 (0.42) | LMNAALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5566727 | 0.77 | TSHR (0.58) | TSHRTDP1LMNAALDH1A1CYP2D6 | |
| SCHEMBL5566020 | 0.77 | TSHR (0.58) | TSHRTDP1LMNAALDH1A1CYP2D6 | |
| SCHEMBL11186081 | 0.77 | ESR1 (0.46) | ESR1ESR2PDCD1CD274TAAR1 | |
| SCHEMBL2598805 | 0.77 | TSHR (0.58) | TSHRTDP1LMNAALDH1A1CYP2D6 | |
| SCHEMBL9181782 | 0.77 | ESR1 (0.46) | ESR1ESR2PDCD1CD274TAAR1 | |
| SCHEMBL11747478 | 0.76 | TSHR (0.55) | TSHRALOX15ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040260084-A1 | Novel c-3 s/o-and s/n formaldehe acetal derivatives of cephalosporins and their use as antibotics | PFAENDLER HANS R (DE) | 2004-12-23 | — | — | US | claimed |
| EP-1444237-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | Pfaendler, Hans Rudolf (DE) | 2004-08-11 | — | — | EP | claimed |
| WO-2003042219-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | PFAENDLER HANS RUDOLF (DE) | 2003-05-22 | — | — | WO | claimed |
| US-20040260084-A1 | Novel c-3 s/o-and s/n formaldehe acetal derivatives of cephalosporins and their use as antibotics | PFAENDLER HANS R (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1444237-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | Pfaendler, Hans Rudolf (DE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003042219-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | PFAENDLER HANS RUDOLF (DE) | 2003-05-22 | — | — | WO | disclosed |
| US-5532353-A | Process for the preparation of halogenated β-lactam compounds | BIOCHIMICA OPOS SPA (IT) | 1996-07-02 | — | — | US | disclosed |
| EP-0570058-A2 | Process for the preparation of halogenated beta-lactam compounds | BIOCHIMICA OPOS SPA (IT) | 1993-11-18 | — | — | EP | disclosed |
| US-4992544-A | Intermediates for b-lactam antibiotics and b-lactamase inhibitor | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1991-02-12 | — | — | US | disclosed |
| US-4537720-A | N-substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamino)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| US-4533497-A | N-ethylidene azetidinones | ELI LILLY AND COMPANY (US) | 1985-08-06 | — | — | US | disclosed |
| US-4064343-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
| US-4060688-A | Cephalosporin intermediates | ELI LILLY AND COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
| US-4044000-A | Substituted β-lactam antibiotics | ELI LILLY AND COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
| US-4013651-A | 3-SUBSTITUTED AMINO-CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3994885-A | WITH ALKALI METAL ALKOXIDE, HALOGENATION | ELI LILLY AND COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3992377-A | 3-Thio-substituted cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3985737-A | ANTIBACTERIAL AGENTS | ELI LILLY AND COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3962227-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3954731-A | Process for preparing 6-alkoxypenicillanic and 7-alkoxycephalosporin acids | ELI LILLY AND COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260084-A1 | Novel c-3 s/o-and s/n formaldehe acetal derivatives of cephalosporins and their use as antibotics | CBR3, CBR1, SULT1E1 | ESR1 1678/4885ESR2 1260/4885PDCD1 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.